LY4337713 / Eli Lilly - LARVOL DELTA

FiREBOLT: A phase 1 study evaluating radioligand therapy with LY4337713 in adults with select FAP+ solid tumors (Trial in progress) (AACR 2026) - P1 | "JNM. 2025, 66(1):251266"

Clinical • P1 data • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Ovarian Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Triple Negative Breast Cancer • HER-2

FiREBOLT: A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (clinicaltrials.gov) - P1 | N=241 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Platinum resistant • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

FiREBOLT: A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (clinicaltrials.gov) - P1 | N=241 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor